By comparing these therapeutic approaches, this study seeks to elucidate whether SGLT2 inhibitors offer a multifaceted advantage in managing T2DM and CKD, potentially reducing therapeutic inertia and easing polypharmacy by addressing multiple risk factors with a single agent. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.